Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

The novel clinical-stage β-lactam-β-lactamase inhibitor combination, cefepime-taniborbactam, demonstrates promising activity toward many Gram-negative bacteria producing class A, B, C, and/or D β-lactamases. We tested this combination against a panel of 150 Burkholderia cepacia complex (Bcc) and Bur...

Descripción completa

Detalles Bibliográficos
Autores principales: Mojica, Maria F., Zeiser, Elise T., Becka, Scott A., LiPuma, John J., Six, David A., Moeck, Greg, Papp-Wallace, Krisztina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648927/
https://www.ncbi.nlm.nih.gov/pubmed/37768313
http://dx.doi.org/10.1128/aac.00498-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648927/
https://www.ncbi.nlm.nih.gov/pubmed/37768313
http://dx.doi.org/10.1128/aac.00498-23

Ejemplares similares